An orally delivered small-molecule formulation with antiangiogenic and anticancer activity

Nature Biotechnology

Volumn 26, Issue 7, 2008, Pages 799-807

  Benny, Ofra ^a   Fainaru, Ofer ^a   Adini, Avner ^a   Cassiola, Flavia ^a   Bazinet, Lauren ^a   Adini, Irit ^a   Pravda, Elke ^a   Nahmias, Yaakov ^b   Koirala, Samir ^c   Corfas, Gabriel ^c   D'Amato, Robert J ^a   Folkman, Judah ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; COLLOIDS; DRUG DELIVERY; DRUG DOSAGE; DRUG THERAPY; ETHYLENE GLYCOL; GLYCOLS; LIVER; PATHOLOGY; POLYETHYLENE GLYCOLS; TUMORS; WEIGHT CONTROL;

ANGIOGENESIS; ANGIOGENESIS INHIBITORS; ANTIANGIOGENIC; ANTICANCER ACTIVITIES; CANCER THERAPIES; FUMAGILLIN; ORAL ROUTE; PARENTERAL ADMINISTRATION; POLY-LACTIC ACID (PLA); SMALL MOLECULES; TUMOR GROWTH;

BLOOD VESSELS;

COUMARIN; FUMAGILLOL CHLOROACETYLCARBAMATE; LODAMIN; MACROGOL; MONOMETHOXYPOLYETHYLENEGLYCOL; POLYLACTIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG MEGADOSE; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; LEWIS CARCINOMA; LIVER METASTASIS; MALE; MELANOMA; MICELLE; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYCLOHEXANES; HUMANS; LUNG NEOPLASMS; MICE; NEOVASCULARIZATION, PATHOLOGIC; SESQUITERPENES; TREATMENT OUTCOME;

MUS;

EID: 46949110744     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1415     Document Type: Article

References (42)

1. Holmgren, L., O'Reilly, M. & Folkman, J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1, 149-153 (1995).
2. Naumov, G. & Folkman, J. Strategies to prolong the nonangiogenic dormant state of human cancer. in Antiangiogenic cancer therapy Edn. 1. (ed. Darren, W., Herbst, R.S., Abbruzzese, J.L.) 3-23 (CRS Press, Boca Raton, FL, Taylor and Francis, 2007).
3. Ingber, D. et al. Synthetic analogue of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348, 555-557 (1990).
4. Folkman, J. & Kalluri, R. Tumor angiogenesis. in Cancer Medicine Vol. 1. (ed. Kufe, D. et al.) 161-194 (B.C. Decker Inc., Hamilton, Ontario, 2003).
5. Yamaoka, M., Yamamoto, T., Ikeyama, S., Sudo, K. & Fujita, T. Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res. 53, 5233-5236 (1993).
6. Shusterman, S. et al. The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. Clin. Cancer Res. 7, 977-984 (2001).
7. Yanase, T., Tamura, M., Fujita, K., Kodama, S. & Tanaka, K. Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res. 53, 2566-2570 (1993).
8. Takamiya, Y., Brem, H., Ojeifo, J., Mineta, T. & Martuza, R. AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo. Neurosurgery 34, 869-875 (1994).
9. Takamiya, Y., Friedlander, R.M., Brem, H. & Malick, A. Martuza, RL Inhibition of angiogenesis and growth of human nerve-sheath tumors by AGM-1470. J. Neurosurg. 78, 470-476 (1993).
10. Emoto, M., Tachibana, K., Iwasaki, H. & Kawarabayashi, T. Antitumor effect of TNP-470, an angiogenesis inhibitor, combined with ultrasound irradiation for human uterine sarcoma xenografts evaluated using contrast color Doppler ultrasound. Cancer Sci. 98, 929-935 (2007).
11. Nahari, D. et al. Tumor cytotoxicity and endothelial Rac inhibition induced by TNP-470 in anaplastic thyroid cancer. Mol. Cancer Ther. 6, 1329-1337 (2007).
12. Kanamori, M., Yasuda, T., Ohmori, K., Nogami, S. & Aoki, M. Genetic analysis of high-metastatic clone of RCT sarcoma in mice, and its growth regression in vivo in response to angiogenesis inhibitor TNP-470. J. Exp. Clin. Cancer Res. 26, 101-107 (2007).
13. Sin, N. et al. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc. Natl. Acad. Sci. USA 94, 6099-6103 (1997).
14. Zhang, Y., Griffith, E., Sage, J., Jacks, T. & Liu, J. Cell cycle inhibition by the antiangiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. Proc. Natl. Acad. Sci. USA 97, 6427-6432 (2000).
15. Mauriz, J. et al. Cell-cycle inhibition by TNP-470 in an in vivo model of hepatocarcinoma is mediated by a p53 and p21WAF1/CIP1 mechanism. Transl. Res. 149, 46-53 (2007).
16. Kruger, E. & Figg, W.D. TNP-470: an angiogenesis inhibitor in clinical development for cancer. Expert Opin. Investig. Drugs 9, 1383-1396 (2000).
17. Kudelka, A., Verschraegen, C. & Loyer, E. Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. N. Engl. J. Med. 338, 991-992 (1998).
18. Tran, H. et al. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother. Pharmacol. 54, 308-314 (2004).
19. Kudelka, A. et al. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin. Cancer Res. 3, 1501-1505 (1997).
20. Herbst, R. et al. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J. Clin. Oncol. 20, 4440-4447 (2002).
21. Stadler, W. et al. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J. Clin. Oncol. 17, 2541-2545 (1999).
22. Logothetis, C. et al. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin. Cancer Res. 7, 1198-1203 (2001).
23. Bhargava, P. et al. A phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin. Cancer Res. 5, 1989-1995 (1999).
24. Satchi-Fainaro, R. et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat. Med. 10, 255-261 (2004).
25. Cretton-Scott, E., Placidi, L., McClure, H., Anderson, D. & Sommadossi, J. Pharmacokinetics and metabolism of O-(chloroacetyl-carbamoyl) fumagillol (TNP-470, AGM-1470) in rhesus monkeys. Cancer Chemother. Pharmacol. 38, 117-122 (1996).
26. Kataoka, K., Harada, A. & Nagasaki, Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug Deliv. Rev. 47, 113-131 (2001).
27. Harris, J. & Chess, R. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2, 214-221 (2003).
28. Edlund, U. & Albertsson, A. Degradable polymer microspheres for controlled drug delivery. Adv. Polym. Sci. 157, 67-112 (2001).
29. Rogers, M., Birsner, A. & D'Amato, R. The mouse cornea micropocket angiogenesis assay. Nat. Protoc. 2, 2545-2550 (2007).
30. Carter, R., Morton, A. & Dunnett, S. Motor coordination and balance in rodents. in Current Protocols in Neuroscience Vol. 8.12. (ed. Taylor G.), 1-8 (John Wiley & Sons, Inc, New York, 2001).
31. Almog, N. et al. Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. FASEB J. 20, 947-949 (2006).
32. Marler, J. et al. Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies. Pediatrics 116, 38-45 (2005).
33. Folkman, J. & Klement, G. Platelet biomarkers for the detection of disease. US and International Patent 20060204951 (2006).
34. Cervi, D. et al. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood (2007).
35. Kwon, Y. Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists. (Plenum, New York, 2001).
36. Pierri, E. & Avgoustakis, K. Poly(lactide)-poly(ethylene glycol) micelles as a carrier for griseofulvin. J. Biomed. Mater. Res. A 75, 639-647 (2005).
37. Kakizawa, Y. & Kataoka, K. Block copolymer micelles for delivery of gene and related compounds. Adv. Drug Deliv. Rev. 54, 203-222 (2002).
38. Torchilin, V. Targeted polymeric micelles for delivery of poorly soluble drugs. Cell. Mol. Life Sci. 61, 2549-2559 (2004).
39. Nishiyama, N. & Kataoka, K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol. Ther. 112, 630-648 (2006).
40. Barbera-Guillem, E., Smith, I. & Weiss, L. Cancer-cell traffic in the liver. I. Growth kinetics of cancer cells after portal-vein delivery. Int. J. Cancer 52, 974-977 (1992).
41. Greish, K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J. Drug Target. 15, 457-464 (2007).
42. Duncan, R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 6, 688-701 (2006).